Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

A breakthrough for brain tumor drug development

06.02.2019

A breakthrough for brain tumor drug development and personalized medicine published today in Nature

A breakthrough for brain tumor drug development and personalised medicine published today in Nature Scientific Reports.


VIDEO: SpheroMatrices is a spheroid tissue microarray that allows users to capture an entire 3D experiment on a single microscope slide providing a window into the structural and molecular information of the 3D model.With SpheroMatrices technology you can obtain detailed molecular information about the effects of candidate drugs on human tissue models, combining the benefits of 3D cultures with high throughput histology. Thus spheroMatrices maximizes the information obtained from costly 3D cell culture experiments.

Credit: Simon Plummer MicroMatrices CEO

24,000 patients are diagnosed with brain tumors every year with the 5yr survival for high grade glioblastomas (GBM) only 5%, with median survival of 15 months.

These poor statistics have remained static for 30 years due in part to a lack of human-relevant preclinical models for testing new drugs. In addition, high levels of inter-individual cellular and molecular heterogeneity of disease means each patient has unique treatment requirements, however the rapid pace of disease progression allows little time for individual assessments.

To address these challenges a multidisciplinary team of researchers in a public/private collaboration (MicroMatrices, Johns Hopkins University, the Mayo Clinic, and Perkin Elmer) have developed and evaluated a human induced pluripotent stem cell (IPSC) derived 3D organoid model for drug testing consisting of differentiated neurons and other non-neuronal brain cells (glial cells, astrocytes and oligodendrocytes) grown alongside patient-derived glioblastoma tumor cells. Accurate drug efficacy measurements were facilitated through the use of a microTMA-based high throughput histology platform (SpheroMatricesTM).

To investigate the potential of this platform, two chemotherapeutic agents were tested: temozolomide (TMZ), the current front line treatment option for glioblastoma, and an experimental therapy doxorubicin (DOX).

The study results indicated the system could predict a clinical response to TMZ and also demonstrated anti-tumor efficacy with DOX . Furthermore as the microTMA technology allows for multiplexing of different measurements, it was also observed that DOX acted via selective killing of tumour cells (apoptosis) with little or no effect on normal brain cells.

This system can be adapted for use with publicly available libraries of glioblastoma patient-derived cell lines, paving the way for the creation of a more efficient discovery platform for new therapies, ultimately offering a more personalized approach by matching patients to therapies that are more likely to work clinically.

In previous screens, the patient-derived cells were grown in immune-compromised mice, a model which cannot capitulate the environment of human tumours. By contrast, the organoid model system more closely mirrors a human-relevant microenvironment.

In addition, the microTMA technology, by making multiple parallel measurements of efficacy end-points, produces quantitative data supporting mechanistic insights and informative biomarkers with greater potential to translate to the clinic.

Simon Plummer CEO of MicroMatrices said 'this breakthrough study illustrates how human relevant 3D models can make an impact for drug development and personalised medicine'.

Media Contact

Simon Plummer
simonplummer@micromatrices.com
07-973-502-994

http://www.micromatrices.com 

Simon Plummer | EurekAlert!
Further information:
http://dx.doi.org/10.1038/s41598-018-38130-0

More articles from Life Sciences:

nachricht New mechanisms regulating neural stem cells
21.02.2019 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht A landscape of mammalian development
21.02.2019 | Max-Planck-Institut für molekulare Genetik

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Light from a roll – hybrid OLED creates innovative and functional luminous surfaces

Up to now, OLEDs have been used exclusively as a novel lighting technology for use in luminaires and lamps. However, flexible organic technology can offer much more: as an active lighting surface, it can be combined with a wide variety of materials, not just to modify but to revolutionize the functionality and design of countless existing products. To exemplify this, the Fraunhofer FEP together with the company EMDE development of light GmbH will be presenting hybrid flexible OLEDs integrated into textile designs within the EU-funded project PI-SCALE for the first time at LOPEC (March 19-21, 2019 in Munich, Germany) as examples of some of the many possible applications.

The Fraunhofer FEP, a provider of research and development services in the field of organic electronics, has long been involved in the development of...

Im Focus: Regensburg physicists watch electron transfer in a single molecule

For the first time, an international team of scientists based in Regensburg, Germany, has recorded the orbitals of single molecules in different charge states in a novel type of microscopy. The research findings are published under the title “Mapping orbital changes upon electron transfer with tunneling microscopy on insulators” in the prestigious journal “Nature”.

The building blocks of matter surrounding us are atoms and molecules. The properties of that matter, however, are often not set by these building blocks...

Im Focus: University of Konstanz gains new insights into the recent development of the human immune system

Scientists at the University of Konstanz identify fierce competition between the human immune system and bacterial pathogens

Cell biologists from the University of Konstanz shed light on a recent evolutionary process in the human immune system and publish their findings in the...

Im Focus: Transformation through Light

Laser physicists have taken snapshots of carbon molecules C₆₀ showing how they transform in intense infrared light

When carbon molecules C₆₀ are exposed to an intense infrared light, they change their ball-like structure to a more elongated version. This has now been...

Im Focus: Famous “sandpile model” shown to move like a traveling sand dune

Researchers at IST Austria find new property of important physical model. Results published in PNAS

The so-called Abelian sandpile model has been studied by scientists for more than 30 years to better understand a physical phenomenon called self-organized...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Global Legal Hackathon at HAW Hamburg

11.02.2019 | Event News

The world of quantum chemistry meets in Heidelberg

30.01.2019 | Event News

Our digital society in 2040

16.01.2019 | Event News

 
Latest News

A Volcanic Binge And Its Frosty Hangover

21.02.2019 | Earth Sciences

Cleaning 4.0 in the meat processing industry – higher cleaning efficiency

21.02.2019 | Trade Fair News

New mechanisms regulating neural stem cells

21.02.2019 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>